← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Dipeptidyl peptidase 4 (DPP-4) inhibitors
gemigliptin
A10BH06
Adult Dosing
- Type 2 Diabetes Mellitus: 50 mg orally once daily, with or without food
- Renal impairment (eGFR 30-50 mL/min/1.73m2): 50 mg once daily
- Renal impairment (eGFR <30 mL/min/1.73m2 or ESRD): 25 mg once daily
Pediatric Dosing
- Safety and efficacy in pediatric patients (<18 years) have not been established
Indications
- Improvement of glycemic control in adults with type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic agents
Mechanism of Action
- Inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades incretin hormones GLP-1 and GIP
- Increases active levels of incretin hormones, stimulating insulin secretion and suppressing glucagon secretion in a glucose-dependent manner
Contraindications
- History of a serious hypersensitivity reaction to gemigliptin
- Type 1 diabetes mellitus or diabetic ketoacidosis
Adverse Reactions
- Nasopharyngitis
- Hypoglycemia (especially when used with sulfonylureas or insulin)
- Upper respiratory tract infection
- Headache
- Dizziness
- Acute pancreatitis (rare)
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole): Monitor for adverse effects, though dosage adjustment may not be strictly required based on pharmacokinetic profiles
- Sulfonylureas or insulin: Increased risk of hypoglycemia; may require dose reduction of the insulin secretagogue
Curated Content: Needs Vetting Before Put to Clinical Use